Wendell Heidinger, MD
Family Medicine · Grants Pass, ORNPI 1326184607
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 227 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$666
- Novo Nordisk$399
- Lilly USA, LLC$377
- AbbVie$353
- Amgen$336
- Novartis$304
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,14999%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $666 |
| Novo Nordisk | 20 | $399 |
| Lilly USA, LLC | 23 | $377 |
| AbbVie(2 entities) | 21 | $353 |
| Amgen | 17 | $336 |
| Novartis | 15 | $304 |
| Johnson & Johnson | 15 | $278 |
| GSK | 12 | $269 |
| Bayer | 12 | $204 |
| Amarin Pharma, Inc. | 7 | $118 |
| Otsuka America Pharmaceutical, Inc. | 5 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $108 |
| Exact Sciences | 4 | $84 |
| Vanda Pharmaceuticals Inc. | 5 | $80 |
| Eisai Inc. | 4 | $64 |
| Ascendis Pharma Endocrinology Inc | 2 | $48 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Aimmune Therapeutics, Inc. | 2 | $38 |
| Baxter Healthcare | 1 | $35 |
| Mylan Specialty L.p. | 2 | $33 |
| Averitas Pharma Inc. | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $24 |
| Tempus AI, Inc | 1 | $22 |
| Astellas Pharma US Inc | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $12 |
How this compares
$4,172 in reported general payments places this provider in the 95th percentile of 1,221 family medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 61 | $78,259 |
| FarxigaDapagliflozin Propanediol | 59 | $78,248 |
| OzempicSemaglutide | 68 | $73,732 |
| XareltoRivaroxaban | 47 | $68,965 |
| JardianceEmpagliflozin | 57 | $66,258 |
| TrulicityDulaglutide | 34 | $35,615 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $34,423 |
| MounjaroTirzepatide | 31 | $33,718 |
| VascepaIcosapent Ethyl | 27 | $14,003 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 13 | $9,584 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,995 |
| Rosuvastatin Calcium | 352 | $5,830 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 38 | $5,443 |
| Metoprolol Succinate | 229 | $4,040 |
| Gabapentin | 178 | $3,869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $666 | $81,58572 claims |
| Novo NordiskOzempic | $399 | $73,73268 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $20 | $73,25370 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $377 | $69,33365 claims |
| Johnson & JohnsonXarelto | $278 | $68,96547 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $269 | $38,13539 claims |
| AbbVieSynthroid | $353 | $1,94633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in Grants Pass
- Timothy RobertsGrants Pass$5K
- Eden MillerBend$1.7M
- Anil RajaniHood River$325K
- Stephen NelsonMedford$101K
- Karen KahnAshland$86K
- Robert GobboPortland$53K
- Kevin MillerSisters$39K
- Morris MaizelsCentral Point$25K
- Maureen MaysPortland$24K
- Nathaniel FondellMedford$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.